Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuji Baifeng Tablets for decreased ovarian reserve
ChiCTR2100054953Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2021
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tongren Wuji Baifeng Pill in Diminished Ovarian Reserve (DOR) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Follicle-stimulating hormone. Started Aug 2021; status: recruiting.
02
Drugs
Tongren Wuji Baifeng Pill
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on ChiCTR2100054953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054953.